» Articles » PMID: 32316225

Increased MRNA and MiR-17-5p Expression Is Correlated to Invasiveness and Proliferation of Pituitary Neuroendocrine Tumours

Overview
Specialty Radiology
Date 2020 Apr 23
PMID 32316225
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

miR-17-5p and have been described as deregulated in cancer, but they have scarcely been studied in pituitary neuroendocrine tumours (PitNETs). This study evaluates the relationship of and miR-17-5p with the invasiveness and proliferation of PitNETs. In this cross-sectional descriptive study, we evaluated the expression of , , and miR-17-5p by quantitative real time PCR analysis in 60 PitNETs: 29 gonadotroph (GT), 15 functioning somatotroph (ST), and 16 corticotroph (CT) tumours, of which 8 were silent (sCT). The clinical data were collected from the Spanish Molecular Register of Pituitary Adenomas (REMAH) database. We defined invasiveness according to the Knosp classification and proliferation according to a molecular expression of Ki-67 ≥ 2.59. was more expressed in invasive than in non-invasive tumours in the whole series ( = 0.004) and in STs ( = 0.01). In addition, it was overexpressed in the silent subtypes (GTs and sCTs; all macroadenomas) and normoexpressed in the functioning ones (fCTs and STs; some microadenomas). miR-17-5p was more expressed in proliferative than in non-proliferative tumours ( = 0.041) in the whole series but not by subtypes. Conclusions: Our study suggests that in PitNETs, could be a good biomarker of invasiveness, and miR-17-5p of proliferation, helping the clinical management of these tumours.

Citing Articles

Unraveling Therapeutic Opportunities and the Diagnostic Potential of microRNAs for Human Lung Cancer.

Sweef O, Zaabout E, Bakheet A, Halawa M, Gad I, Akela M Pharmaceutics. 2023; 15(8).

PMID: 37631277 PMC: 10459057. DOI: 10.3390/pharmaceutics15082061.


MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus.

Okumura T, Fujii T, Terabayashi K, Kojima T, Takeda S, Kashiwada T Oncol Lett. 2023; 26(1):276.

PMID: 37274462 PMC: 10236049. DOI: 10.3892/ol.2023.13862.


Validation of Myc-Associated Protein X (MAX) regulation in growth hormone secreting and nonfunctional pituitary adenoma.

Tucker D, Pangal D, Du R, Gogia A, Tafreshi A, Ruzevick J PLoS One. 2023; 18(4):e0284949.

PMID: 37104368 PMC: 10138191. DOI: 10.1371/journal.pone.0284949.


High Level of Staufen1 Expression Confers Longer Recurrence Free Survival to Non-Small Cell Lung Cancer Patients by Promoting THBS1 mRNA Degradation.

Bonnet-Magnaval F, Diallo L, Brunchault V, Laugero N, Morfoisse F, David F Int J Mol Sci. 2022; 23(1).

PMID: 35008641 PMC: 8745428. DOI: 10.3390/ijms23010215.


MicroRNAs as Potential Biomarkers in Pituitary Adenomas.

Donati S, Aurilia C, Palmini G, Miglietta F, Falsetti I, Iantomasi T Noncoding RNA. 2021; 7(3).

PMID: 34564317 PMC: 8482103. DOI: 10.3390/ncrna7030055.


References
1.
Matsumura I, Tanaka H, Kanakura Y . E2F1 and c-Myc in cell growth and death. Cell Cycle. 2003; 2(4):333-8. View

2.
Cloonan N, Brown M, Steptoe A, Wani S, Chan W, Forrest A . The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol. 2008; 9(8):R127. PMC: 2575517. DOI: 10.1186/gb-2008-9-8-r127. View

3.
DAngelo D, Esposito F, Fusco A . Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas. Front Med (Lausanne). 2015; 2:39. PMC: 4469109. DOI: 10.3389/fmed.2015.00039. View

4.
Coller H, Forman J, Legesse-Miller A . "Myc'ed messages": myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genet. 2007; 3(8):e146. PMC: 1959363. DOI: 10.1371/journal.pgen.0030146. View

5.
Sylvestre Y, De Guire V, Querido E, Mukhopadhyay U, Bourdeau V, Major F . An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2006; 282(4):2135-43. DOI: 10.1074/jbc.M608939200. View